enGene Therapeutics Statistics
Total Valuation
ENGN has a market cap or net worth of $116.56 million. The enterprise value is -$108.55 million.
| Market Cap | 116.56M |
| Enterprise Value | -108.55M |
Important Dates
The last earnings date was Monday, June 15, 2026, before market open.
| Earnings Date | Jun 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ENGN has 66.99 million shares outstanding. The number of shares has increased by 25.52% in one year.
| Current Share Class | 66.99M |
| Shares Outstanding | 66.99M |
| Shares Change (YoY) | +25.52% |
| Shares Change (QoQ) | +3.66% |
| Owned by Insiders (%) | 0.66% |
| Owned by Institutions (%) | 39.69% |
| Float | 22.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.46 |
| P/TBV Ratio | 0.46 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.57, with a Debt / Equity ratio of 0.13.
| Current Ratio | 12.57 |
| Quick Ratio | 12.07 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -44.42 |
Financial Efficiency
Return on equity (ROE) is -52.58% and return on invested capital (ROIC) is -30.62%.
| Return on Equity (ROE) | -52.58% |
| Return on Assets (ROA) | -28.86% |
| Return on Invested Capital (ROIC) | -30.62% |
| Return on Capital Employed (ROCE) | -46.35% |
| Weighted Average Cost of Capital (WACC) | 3.63% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.55M |
| Employee Count | 82 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -258,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.43% in the last 52 weeks. The beta is -0.29, so ENGN's price volatility has been lower than the market average.
| Beta (5Y) | -0.29 |
| 52-Week Price Change | -47.43% |
| 50-Day Moving Average | 4.22 |
| 200-Day Moving Average | 7.11 |
| Relative Strength Index (RSI) | 33.48 |
| Average Volume (20 Days) | 1,104,964 |
Short Selling Information
The latest short interest is 1.62 million, so 2.42% of the outstanding shares have been sold short.
| Short Interest | 1.62M |
| Short Previous Month | 1.46M |
| Short % of Shares Out | 2.42% |
| Short % of Float | 7.21% |
| Short Ratio (days to cover) | 0.45 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -132.58M |
| Pretax Income | -127.11M |
| Net Income | -126.85M |
| EBITDA | -131.91M |
| EBIT | -132.58M |
| Earnings Per Share (EPS) | -$2.12 |
Balance Sheet
The company has $258.47 million in cash and $33.35 million in debt, with a net cash position of $225.11 million or $3.36 per share.
| Cash & Cash Equivalents | 258.47M |
| Total Debt | 33.35M |
| Net Cash | 225.11M |
| Net Cash Per Share | $3.36 |
| Equity (Book Value) | 255.17M |
| Book Value Per Share | 3.81 |
| Working Capital | 248.52M |
Cash Flow
In the last 12 months, operating cash flow was -$110.00 million and capital expenditures -$1.39 million, giving a free cash flow of -$111.39 million.
| Operating Cash Flow | -110.00M |
| Capital Expenditures | -1.39M |
| Depreciation & Amortization | 670,000 |
| Net Borrowing | 1.25M |
| Free Cash Flow | -111.39M |
| FCF Per Share | -$1.66 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ENGN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.52% |
| Shareholder Yield | -25.52% |
| Earnings Yield | -108.83% |
| FCF Yield | -95.56% |
Analyst Forecast
The average price target for ENGN is $3.29, which is 89.08% higher than the current price. The consensus rating is "Hold".
| Price Target | $3.29 |
| Price Target Difference | 89.08% |
| Analyst Consensus | Hold |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |